Effect of a nanostructured dendrimer-naloxonazine complex on endogenous opioid peptides mu(1) receptor-mediated post-ictal antinociception
Nenhuma Miniatura disponível
Data
2011-12-01
Autores
Felippotti, Tatiana Tocchini
do Carmo, Devaney Ribeiro [UNESP]
Paim, Leonardo Lataro [UNESP]
Stradiotto, Nelson Ramos [UNESP]
Bicalho, Urquisa de Oliveira [UNESP]
Parada, Carlos Amilcar
Grillo, Renato [UNESP]
Fraceto, Leonardo Fernandes [UNESP]
Coimbra, Norberto Cysne
Título da Revista
ISSN da Revista
Título de Volume
Editor
Elsevier B.V.
Resumo
The aim of this study was to investigate the capacity of the host dendrimer DAB-Am-16 as a drug carrier to reduce the time required for the encapsulated naloxonaxine to establish an irreversible covalent bond with mu(1)-opioid receptor (resulting in a pharmacologically selective effect). The efficacy of dendrimer-naloxonazine nanocomplex (DNC) was studied in antinociception induced by convulsions elicited by intraperitoneal (IP) administration of pentylenetetrazole, and analgesia was measured by the tail-flick test. We found that animals showed increased tail-flick latencies following convulsions. Furthermore, acute pre-treatment (10 minutes) with DNC, but not with naloxonazine alone, antagonized post-ictal analgesia in comparison with control pre-treatment. However, naloxonazine treatment 24 hours before PTZ decreased post-ictal antinociception, but DNC failed to antagonize tonic-clonic seizure-induced analgesia. In addition, according to Racine's index of seizure severity, naloxonazine, DAB-Am-16 dendrimer or DNC did not influence seizure severity when administered either 10 minutes or 24 hours before PTZ.From the Clinical Editor: This study characterizes the effect of a dendrimer-naloxonazine complex on mu(1) receptor-mediated post-ictal antinociception in an animal model of seizure disorder. (C) 2011 Elsevier B.V. All rights reserved.
Descrição
Palavras-chave
DAB-Am-16 Dendrimer, GABA-A receptor, mu(1)-opioid receptor, Post-ictal analgesia, nanostructured materials
Como citar
Nanomedicine-nanotechnology Biology and Medicine. Amsterdam: Elsevier B.V., v. 7, n. 6, p. 871-880, 2011.